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Introduction: The Stroke and Cognition consortium (STROKOG) aims to facilitate a better under-
standing of the determinants of vascular contributions to cognitive disorders and help improve the 
diagnosis and treatment of vascular cognitive disorders (VCD). 
Methods: Longitudinal studies with 2_75 participants who had suffered or were at risk of stroke or 
TIA and which evaluated cognitive function were invited to join STROKOG. The consortium will 
facilitate projects investigating rates and patterns of cognitive decline, risk factors for VCD, and bio-
markers of vascular dementia. 
Results: Currently, STROKOG includes 25 (21 published) studies, with 12,092 participants from 
five continents. The duration of follow-up ranges from 3 months to 21 years. 
Discussion: Although data harmonization will be a key challenge, STROKOG is in a unique position 
to reuse and combine international cohort data and fully explore patient level characteristics and out-
comes. STROKOG could potentially transform our understanding of VCD and have a worldwide 
impact on promoting better vascular cognitive outcomes. 
© 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association. This is an 
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ 
4.0/). 
Cohort studies; Vascular dementia; Post-stroke dementia; Vascular cognitive disorder; Small vessel disease; Data 
harmonization; International consortium 
1. Introduction lence of VaD was 0.3% in the age group 65-69 years and 
5.2% in those aged 90 and above, and VaD accounted for 
15.8% of all dementias in these studies [2]. The Canadian 
Study of Health and Aging used a broader concept termed 
vascular cognitive impairment (VCI) which consisted of 
three subgroups: VCI with no dementia, VaD, and AD with 
a vascular component. The authors estimated that approxi-
mately 5% of people over the age of 65 years had VCI, 
with 2.4% having VCI with no dementia, 0.9% having mixed 
(vascular and neurodegenerative) dementia and 1.5% having 
VaD [3]. Various clinical studies have shown that the preva-
lence of dementia is much greater in post-stroke patients, 
with 6 to 32% being reported as having dementia three 
months after stroke [3-8]. A systematic review reported 
that dementia is 3.5 to 5.6 fold more frequent in patients 
with stroke than in stroke-free controls [9]. Because risk fac-
tors for stroke are modifiable, and its incidence has been 
Vascular cognitive disorders (VCDs) are a heterogeneous 
group of neurocognitive disorders with the salient feature 
being that cognitive decline is primarily attributable to cere-
brovascular disease. The term VCD has a chequered history, 
and it includes not only vascular dementia (VaD; e.g., post-
stroke and multi-infarct dementia), but also cognitive 
impairment of vascular origin that does not meet the criteria 
for dementia. VaD is common and is generally considered to 
be the second most common form of dementia, after 
Alzheimer's disease (AD) [1]. 
The prevalence and incidence of VCD varies depending 
on the diagnostic criteria applied and the populations studied. 
In 11 population-based European studies conducted in the 
1990s, the age-standardized prevalence of VaD was esti-
mated to be 1.6% compared to 4.4% for AD [2] ; the preva-
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shown to change with public health intervention, stroke may 
be regarded as a powerful and modifiable risk factor for de-
mentia [10]. 
Poststroke dementia has emerged as an important subset of 
VCD primarily because of the large impact stroke has on the 
risk of VCD. The cognitive consequences of stroke as well as 
the associated burden of increased functional dependency, insti-
tutionalization, and mortality rates are increasingly being recog-
nized [ 11]. However, many aspects of poststroke dementia are 
uncertain [5], and the precise impact of a stroke on pre-
existing cognitive impairment has been disputed. Patients 
with stroke usually have a complex combination of large and 
small vessel disease in the brain; in older patients in particular, 
nonvascular pathology such as AD may also be present [12]. 
Some studies found that up to 10% of stroke patients have 
cognitive impairment that could be classified as dementia before 
their first stroke [4,5,8], a finding that may be attributable to 
previous silent infarcts, noninfarct small vessel disease or AD 
pathology, or a combination of these. An American case-
control longitudinal study reported that a stroke doubles the 
risk of dementia, that this excess risk diminishes with time, 
and that it does not apply to those >85 years [13]. According 
to a recent systematic review and meta-analysis, about one-
tenth of patients develop new dementia soon after first stroke, 
and over one-third are demented after a recurrent stroke [8]. 
Although older age and low levels of education have 
consistently emerged as key predictors of worse cognitive 
outcome soon after stroke [8,14], studies have shown 
inconsistent findings in relation to other risk factors, which 
include cerebrovascular disease risk factors such as 
diabetes mellitus and atrial fibrillation, prior pathology, 
stroke features, and infarct characteristics [8,9,15]. 
Making better use of existing data to improve stroke and 
dementia prevention and treatment is a priority for many 
governments and funders. The Joint Program for Neurode-
generation (JPND) thus recently funded several initiatives 
to improve data usage. Metacohorts is one of these initiatives 
focused on vascular contributions to dementia and the group 
identified over 90 studies, including over 600,000 subjects 
worldwide that included data relevant to vascular effects 
on neurodegeneration including cognitive consequences of 
stroke [16]. 
Stroke and Cognition consortium (STROKOG) is a 
recently established consortium of prospective post-stroke/ 
TIA studies from around the world, including, at the time 
of writing, 25 studies with up to 12,092 patients from 16 
countries and 25 institutions worldwide. By harmonizing 
data and conducting individual participant data (IPD) 
meta-analyses on studies from around the world, STRO-
KOG aims to better understand the longitudinal course of 
poststroke cognitive impairment and investigate differences 
in the prevalence of VCD as well as risk and protective fac-
tors between different countries and ethnic groups. In IPD 
meta-analysis, the original research data are sought directly 
from the researchers responsible for each study rather 
than extracting summary (aggregate) data from study 
publications or from investigators. The original data can 
then be re-analyzed centrally and combined, if appropriate, 
in meta-analyses. There are various advantages of con-
ducting IPD meta-analyses over standard meta-analysis, 
such as the ability to investigate patient level characteristics, 
adjust for the same confounding factors across studies, 
address new research questions, and reduce publication 
bias [17,18]. By harmonizing and conducting analyses on 
a rich collection of individual participant data, STROKOG 
can examine risk factors on the patient level and apply 
standardized methods of statistical analyses and dementia 
diagnosis that could produce more accurate prevalence 
estimates and more detailed information on the risk 
factors for VCD and the impact stroke has on cognitive 
decline. It is anticipated that the findings of STROKOG 
will help guide and optimize preventative strategies and 
health policy worldwide. STROKOG was officially 
established at the VASCOG (Society for the Study of 
Vascular Cognitive and Behavioral Disorders) 2015 
meeting in Tokyo, Japan. 
2. Methods 
2.1. Membership 
Studies are eligible to participate in STROKOG if they 
meet the following membership criteria: 
1. Prospectively recruited patients with stroke, TIA, or 
high-stroke risk (such as patients with atrial fibrilla-
tion, hypertension, genetic disorders such as CADA-
SIL and so forth). 
2. Are longitudinal, with a minimum of two waves of as-
sessments conducted or planned. 
3. Have a minimum sample size of 75. 
4. The major outcome measures include dementia and/or 
cognitive impairment and/or cognitive decline. 
Official enrollment requires the study lead investigator to 
sign a memorandum of understanding (MoU) which spec-
ifies a willingness to share nonidentifiable data for joint an-
alyses. Studies that have restrictions on data use and data 
sharing may also participate in STROKOG by conducting 
in-house analyses using STROKOG protocols and providing 
summary data for pooling. 
At the time of writing, there are 24 officially enrolled 
member studies of STROKOG and one unofficial member 
study which plan to obtain participants' permission to share 
data before signing the MoU. These studies and their key 
demographic characteristics are shown in Table 1. 
Supplementary Table S 1 shows some salient findings from 
each member study. They represent 16 different countries, 
including one lower middle income country from across 
five continents (Africa, Asia, Australia, Europe, and North 
America). In total, there are 12,092 participants, and for 
most studies, patients were recruited consecutively as they 
were admitted to hospital with a recent stroke. 
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Approximately half of the studies admitted participants with 
a recent TIA, and those with a previous stroke were typically 
not excluded. The longest follow-up duration of the studies 
is 21 years and the median is 3 years. Table 2 shows the list of 
neuropsychological tests used in each study. 
2.2. Organization 
The STROKOG Research Steering Committee (RSC) 
consists of a representative from each of the contributing 
studies, generally the lead investigator or a delegate. The pri-
mary functions of the RSC are to 
1. Develop guidelines for the inclusion and exclusion of 
studies. 
2. Provide rules of participation and guidelines for the 
roles and responsibilities of the participating studies. 
3. Approve Work Groups (see research projects below). 
4. Select topics of interest. 
5. Provide overall analytic strategies. 
6. Develop rules for publication, including authorship. 
7. Develop rules for the protection of intellectual prop-
erty, when relevant. 
8. Seek funds to support STROKOG. 
2.3. Meetings 
An initial meeting of many study leaders at the VASCOG 
2015 conference in Tokyo on 16 September 2015 supported 
the official establishment of STROKOG. The proposed 
structure of the consortium, including the functions of the 
RSC and proposed projects were discussed. A second inter-
national meeting was held at VASCOG 2016 in Amsterdam 
on 14 October 2016. Preliminary findings from the first proj-
ect were presented and potential projects were discussed. 
2.4. Website 
A website that contains a description of STROKOG and 
summaries of the member studies has been established 
(https://cheba.unsw.edu.au/group/strokog). The website is 
intended to serve as an avenue for presenting and preserving 
STROKOG project protocols and results. 
2.5. Ethics 
The overall STROKOG project has been approved by 
the Human Research Ethics Committee (HREC) of the 
University of New South Wales (UNSW), Sydney (refer-
ence number: HC14359). Member studies are responsible 
for obtaining approval (if necessary) from their local 
institutional review board for the sharing of data. 
Although de-identified data are not considered Protected 
Health Information by the National Institutes of Health 
of the United States, ethics review boards differ in 
their approach to this matter. A protocol for the de-
identification of data has been developed. Additionally, 
each new project presented to STROKOG must be 
approved by an institutional review board and the 
HREC of UNSW informed about the project. 
2.6. Research projects and data 
The Sydney team will initiate the first project, collate 
study data and conduct the initial data harmonization and 
IPD meta-analyses across the different studies. STROKOG 
will follow guidelines for rigorous and effective harmoni-
zation [58] as well as for IPD meta-analyses and reporting 
[17,59] . Original data sets supplied by members and the 
harmonized data sets, which will include derived data, 
will be held by the Sydney team on a secure database at 
the University of New South Wales. A STROKOG RSC 
member can propose a research project, which need to 
undergo an approval process by the RSC. If the 
prospective proposer of a project is not a member of the 
RSC or affiliated with a member study, the proposal can 
still go ahead if it is sponsored by a member of the RSC. 
A student may similarly request data for a research 
project if sponsored by a member of the RSC. Once 
approved, the proposer will be advised to form a Work 
Group for the specific project, with a clearly identified 
project leader. Other members of the consortium may 
volunteer to be part of the Work Group if they have a 
clear interest and expertise in the research project. The 
Work Group will address and be responsible for the 
planning, analysis, and publication of the approved 
project. Data held by STROKOG will be released to the 
Work Group; newly joined and existing member studies 
will be requested to provide additional de-identified data. 
Each cohort can opt-in or opt-out of participation; opting-
in represents a commitment to collaborate on the project. 
The central STROKOG data repository at UNSW, Sydney, 
will hold a copy of the data sets used for each project. The 
STROKOG data will not be used or accessed for any pur-
pose other than contributing to an approved STROKOG 
project. 
3. Discussion 
3.1. Challenges 
Large international consortia face general challenges that 
include efficient communication among personnel involved 
with studies across different countries and a need for addi-
tional funding to enable the further use of previously 
collected data. Such challenges have been previously 
described by other consortia (e.g., by CHARGE [60]). 
Challenges more specific to STROKOG are those associated 
with data harmonization, many of which have also been previ-
ously described [61,62]. Neuropsychological test data are likely 
to be the most challenging set of data to be harmonized across 
studies due to heterogeneity in test instruments, administration, 
and criteria for defining impairment; however, the Sydney team 
has had experience harmonizing large data sets from diverse 
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Table 1 
STROKOG member studies 
Sample Follow-up Cognitive MRI 
Study Country Period size* schedule assessments assessments t Dementia criteria Key reference(s) 
Action on Secondary Ireland 2011-2012 256 6m 6mo No NA Mellon et al. 
Prevention (2015) [19] 
Interventions and 
Rehabilitation in 
Stroke (ASPIRE-Si 
Bundang VCI cohort Korea 2007- 918 3m, ly, 3 mo, 1 y, Initial, 1-3 y DSM-IV Lim et al. 
(Bundang-VCI) ongoing 2y, 3y; 2 y, 3 y; (2014) [20] 
ongoing ongoing 
Clinical Biological and France 2005-2015 477 3m, Sy Sy Initial, 5 y NA Ducroquet et al. 
Pharmacological (2013) [21] 
Factors Influencing 
Stroke Outcome 
(BIOSTROKE) 
Cognition and Affect Netherlands 2013-2016 250 3m, 9m, 15m 3 mo, 9mo, 3mo DSM-V, NINCDS- Douven et al. 
after Stroke: 15 mo ADRDA, NINOS- (2016) [22] 
Prospective AIREN 
Evaluation of Risks 
(CASPER) 
Cognition and Australia 2014-2018 135 lm,3m, 3 mo, 1 y, 3 y Initial, 3 mo, DSM, Brodtmann et al. 
Neocortical Volume ly, 3y 1 y, 3 y NINOS- (2014) [23] 
After Stroke AIREN 
(CANVAS) 
Cognitive Function UK 2002-2012 355 3m; l-8y 3 mo; 1-8 y 3 mo, 2y Yes Allan et al. 
After Stroke (annually) (annually) (2011) [12] 
(CogFAST-UK) 
Cognitive Function Nigeria 2010-- 217 3m 3mo 3mo DSM-IV, Akinyerni et al. 
After Stroke Nigeria ongoing (small AIWASA (2014) [24] 
(CogFAST-Nigeria) subset only) 
Cognitive Outcome Singapore 2009-2017 400 3-6m, ly, 3-6 mo, 1 y, Initial (small DSM-IV Dong et al. 
After Stroke (planned) 3-4y, Sy, 3-4 y, 5 y, subset only) (2012) [25] 
(COAST) 6y, 7y 6 y, 7 y 
Cracow Stroke Poland 2000--2001 250 3m, 12m 3 mo, 12mo No DSM-IV Klimkowicz et al. 
Database (Cracow) (2004; 2006) 
[26,27] 
Determinants of Germany 2011-2019 600 3m,6m, 6 mo, 1 y, Initial, 6 mo; DSM-V Wollenweber et al. 
Dementia After (planned) ly, 2y, 3y, 3 y, 5 y; 3 y, 5 y (2013) [28] 
Stroke 4y,5y (TICS 
(OEDEMAS) only: 3 mo, 
2 y, 4 y) 
Durban Stroke Data South Africa 1992-1998 1000 3m, 6m, 12m Initial, 3, 6, Initial DSM-IV Hoffmann (1998; 
Bank (DSDB) 13mo 2001) [29,30] 
Epiderniologic study of USA 1988-1999 585 Initial, 3 mo-10 y No Modified Desmond et al. 
the risk of dementia 3m-10 y (annually) DSM-III-R (2000, 2002) 
after stroke (Epi (annually) [7,31] 
USA) 
Goteborg 70 + Stroke Sweden 1993- 1994 243 3m, 12m, 18 mo Subset DSM-III-R Linden et al. 
Study (Goteborg 18m (2004; 2007) 
Neuro70+) [32,33] 
Groupe de Reflexion France 2010--2015 360 6m 6mo 6mo VASCOG Godefroy et al. 
pour !'Evaluation (2012) [34] 
COGnitive 
VASCulaire study 
(GRECOG-VASC)§ 
Helsinki Stroke Aging Finland 1993-2015 486 3m, 15m, 3mo Initial DSM Jokinen et al. 
Memory (SAM) 21y (2015) [35]; 
Oksala et al. 
(2009) [36] 
( Continued) 
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Table l 
STROKOG member studies (Continued) 
Sample Follow-up Cognitive MRI 
Study Country Period size* schedule assessments assessments t Dementia criteria Key reference(s) 
Maastricht Cognitive Netherlands 2000--2003 194 lm,6m, 1 mo, 6mo, No DSM-III, Rasquin et al. 
Disorders After ly, 2y l y, 2 y DSM-III-R, (2005) [37] 
Stroke (CODAS) DSM-IV, ICD-10, 
NINDS-AIREN, 
ADDTC 
Mild Stroke Study II UK 2010--2015 264 1-3m, 1-3 mo Initial, ACER;MoCA Heye et al. (2015; 
(MSS-11) l y,3y 1-3 mo, 1 y equivalent; 2016) [38,39], 
NART Valdes 
Hernanadez 
et al. (2015) 
[40] 
Korean-Vascular Korea 2007-2008 620 3m 3 mo Initial DSM-IV Yu et al. 
Cognitive (2013) [41] 
Impairment 
Harmonization 
Standards Study 
(K-VCIHS) 
North East Melbourne Australia 1998-2003 99 3m, ly, 2y 3 mo, l y, No Yes Srikanth et al. 
Stroke Incidence 2y (2003; 2004; 
Study (NEMESIS) 2006) [42-44] 
National Neuroscience Singapore 2011-2017 506 3-6m, l y 3-6 mo, Initial Yes Kandiah et al. 
Institute study (NNI up to Sy 1 y up (2011; 2014, 
Singapore) to 5 y 2016) [45-47] 
Prognosis of France 2004- 562 6 mo, l y, l y, 2 y, 3 y, Initial, 6 mo; Yes Cordonnier et al. 
Intracerebral ongoing 2 y, 3 y, 4.5 y, 6 y, 1 y, 2 y, 3 y, (2010) [48]; 
Hemorrhage 4.5 y, 6 y, 8 y, 10 y 4.5 y, 6 y, Moulin et al. 
(PITCH) 8 y, 10 y 8 y, 10 y (2016) [49] 
Prospective Study of Scotland, 1997-2001 649 9 mo, 1.5 y, Initial, 9 mo, Initial, NA Shepherd et al. 
Pravastatin in the Ireland, 2.5 y, up 1.5 y, 2.5 y, study end (2002) [50] 
Elderly at Risk Netherlands to 3 y study end 
(PROSPER)II 
Stroke Registry Hong Kong 2009-2015 1013 3-6 mo, 1 y, 3-6mo Initial DSM-IV Yang et al. (2015) 
Investigating 2 y, 3 y, [51]; Liu et al. 
Cognitive Decline 4 y, 5 y (2015) [52]; 
(STRIDE) Wang et al. 
(2015a, 2015b) 
[53,54]; 
Mok et al. 
(2016) [55] 
Study of Factors France 2011-2018 1100 6mo, 1 y, 6 mo, l y, Initial, 6 mo, Yes NA 
Influencing Post- (planned) 3 y, 5 y 3 y, 5 y 3 y, 5 y 
Stroke Dementia 
(STROKDEM) 
Sydney Stroke Study Australia 1997- 2005 351 3-6 mo, 1 y, 3-6 mo, 3- 6 mo, 1 y, Consensus Sachdev et al. 
(SSS) 3 y, 5 y 1 y, 3 y, 5 y 3 y, 5 y diagnosis (2004; 2014) 
[56,57] 
Abbreviations: m, month after index stroke; y, years after index stroke; ACER, Addenbrooke's Cognitive Examination; ADDTC, Alzheimer's Disease Diag-
nostic and Treatment Centers; DSM, Diagnostic and Statistical Manual of Mental Disorders; ICD-10, International Statistical Classification of Diseases, 10th 
Revision; MoCA, The Montreal Cognitive Assessment; NART, National Adult Reading Test performance in established dementia; NINCDS-ADRDA, National 
Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association; NINDS-AIREN, National 
Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l'Enseignement en Neurosciences; TICS, Telephone Interview 
for Cognitive Status; VASCOG, International Society for Vascular Behavioral and Cognitive Disorders. 
*Sample size denotes enrollment number (not follow-up) and does not include healthy control subjects. The studies which recruited control subjects were: 
CANVAS (n = 40), CogFAST-Nigeria (n = 74), Epi USA (n = 249), NEMESIS (n = 99), PROSPER and SSS (n = 129). 
tsome studies also obtained PET scans from a subgroup of their participants: GRECOG-VASC (amyloid for 100 patients with poststroke cognitive deficit), 
STROKDEM (at 1 year), OEDEMAS (amyloid/FDG for incident dementia cases), CANVAS (amyloid at 3 years), STRIDE (PiB, n = 50) and DSDB (SPECT, 
n = 36). 
1 ASPIRE-Sis an unofficial member that is planning to obtain participants' permission to share data outside of Ireland before signing the MoU. 
§For the GRECOG-VASC study, only the 200 first patients from the Amiens center are included for STROKOG and the VASCOG criteria was used except for 
the threshold of cognitive impairment which was set at the 5th percentile. 
llpRQSPER shares data at the summary level and not individual participant data. 
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Table 2 
Cognitive measures used by the STROKOG member studies to diagnose dementia 
Cognitive domain 
Attention/processing Construction Executive function/ 
Study speed Memory Language (visuospatial) abstract reasoning 
ASPIRE-S* NA NA NA NA NA 
BIOSTROKE - Trail Making Test A - FCSRT - Verbal fluency, - VOSP - Trail Making Test B 
- Zazzo Test category - Rey Complex - Verbal fluency, letter 
Digit symbol coding - Token Test Figure Test: Copy - Stroop Test 
Bell's Test - Praxis score 
Bundang-VCI Trail Making Test A - Seoul Verbal - Boston Naming Test - Rey Complex - Trail Making Test B 
Digit symbol coding Learning Test - Verbal fluency, Figure Test: Copy - COWAT 
category (animals) 
CASPER Trail Making Test A - RAVLT (15-Word, - Boston Naming Test - Clock-drawing - Trail Making Test B 
Digit Span Forward Dutch) - Verbal fluency, - Digit Span backward 
Digit Symbol Coding category (animals - BADS Zoo map and 
Start Cancellation and professions) key search 
Task 
CANVAS - Trail Making Test A - Hopkins Verbal - Boston Naming Test - Clock-Drawing Test 
- Trail Making Test B 
Digit Span Forward Learning Test - Verbal fluency, - Rey Complex 
- Verbal fluency, letter 
Symbol Digit Mo- - Rey Complex category (animals) Figure Test: Copy (FAS) 
dalities Test Figure Test: Recall - Token Test 
- Cogstate One-Back 
Cogstate Detection Test 
Test and Identifica-
tion Test 
Star Cancellation 
Task 
CogFAST-UK Trail Making Test A - Word-List Memory - Boston Naming Test - Clock-Drawing Test - Verbal fluency, letter 
Simple Reaction - Rivermead - Verbal fluency, - Rey Complex (FAS) 
Time Behavioral category (animals) Figure Test: Copy - Verbal Reasoning 
Choice Reaction Memory Test - Token Test - Visual Reasoning 
Time - Trail Making Test B 
- Number Vigilance - Digit Span backward 
task - Stroop Test 
Digit Span forward 
CogFAST- Choice Reaction - Word-List Learning - Boston Naming Test - Stick Design Test - Verbal fluency, letter 
Nigeria Time Test (10-item) - Verbal fluency, (FAS) 
- Delayed recall of category (animals) - Verbal Reasoning 
stick design - Token Test - Visual Reasoning 
COAST - Digit Span Forward - Word-List Recall - Boston Naming Test - Clock-Drawing Test - Digit Span backward 
- Visual Memory Span - Story Recall - Verbal fluency, - Block Design - Visual memory span 
Forward - Picture Recall (im- category (animals, - Visual reproduction backward 
Auditory Detection mediate and delayed food) copy - Frontal Assessment 
Test recall, and Battery 
Symbol Digit Mo- recognition) - Maze task 
dalities Test - Visual Reproduction 
Digit cancellation (immediate and 
task delayed recall, and 
recognition) 
Cracowt NA NA NA NA NA 
OEDEMAS Trail Making Test A - Word-List Memory - Boston Naming Test - CERAO copy visual - Trail Making Test B 
- Digit Symbol Coding and Recall - Verbal fluency, construction Verbal fluency, letter 
- Discriminability category (animals) - Rey Complex (S-words) 
- Constructional Figure Test: Copy - Stroop Test 
praxis (recall and 
savings) 
- FCSRT 
DSDB - Trail Making Test A - RAVLT - Boston Naming Test - Rey Complex - Trial Making Test B 
Figure Test: Copy - Luria's tests 
- Wisconsin Card 
Sorting Test 
- Verbal fluency, letter 
(FAS) 
( Continued) 
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Table 2 
Cognitive measures used by the STROKOG member studies to diagnose dementia (Continued) 
Cognitive domain 
Attention/processing Construction Executive function/ 
Study speed Memory Language (visuospatial) abstract reasoning 
Epi USA Target finding for - Selective Reminding - Boston Naming Test - Copying geometric - Similarities subtest 
shapes and letters Test - Verbal fluency, figures - Identities and 
- Benton Recognition category - Benton Matching oddities 
Test - Complex Ideation Test - Verbal fluency, letter 
and Repetition sub-
tests of BDAE 
Goteborg NA NA NA NA NA 
Neuro70+ * 
GRECOG- - Trail Making Test A - FCSRT - Boston Naming Test - Rey Complex - Trail Making Test B 
VASC Digit Symbol Coding - Door Visual Recog- - Verbal fluency, Figure Test: Copy - Verbal fluency, letter 
Simple Reaction nition Test category (animals) (PVR) 
Time - Rey Complex - Strategic index 
Digit Tapping Figure Test: Recall (FCSRT) 
Albert cancellation - Inventory of 
test Behavioral 
Dysexecutive 
Disorders 
SAM Trail Making Test A - Logical memory - Boston Naming Test - Block Design - Trail Making Test B 
Stroop color naming - Visual Reproduction - Verbal fluency, - Figure copying test - Digit Span backward 
Digit Span Forward - Fuld Object Memory category (animals) - Clock-Drawing Test - Verbal fluency, 
Bell's Test Evaluation - Token Test - Poppelreuter letter (K) 
- Boston Diagnostic - Stroop Test 
Aphasia Exam - Wisconsin Card 
( overall speech Sorting Test 
evaluation) - Similarities 
- Reading, writing, - Comprehension 
arithmetic operations 
CODAS - Concept Shifting - RAVLT (15-Word, - Verbal fluency, - Clock drawing, - Concept Shifting 
Test Parts A and B Dutch) category (animals, house drawing, Test Part C 
- Letter Digit professions) pentagons, spiral - GIT Analogies 
Substitution Test - GIT Vocabulary (CAMCOG) - Stroop Test 
- Stroop color naming - GIT Mental Rotation 
and reading test 
MSS-11* NA NA NA NA NA 
K-VCIHS Trail Making Test A - Seoul Verbal - Boston Naming Test - Rey Complex - Trail Making Test B 
Digit Symbol Coding Leaming Test - Verbal fluency, Figure Test: Copy - COWAT 
category (animals) 
NEMESIS KSNAP Mental - Rivermead - Rey Complex - KSNAP 4 letter word 
Status Behavioral Memory Figure Test: Copy test 
Digit Span Forward Test - Picture Completion - Similarities 
Digit Symbol Coding - RAVLT - Block Design - Digit Span backward 
KSNAP Number - Rey Complex - KSNAP Gestalt - Verbal fluency, letter 
Recall Figure Test: Recall closure (FAS) 
NNI Digit Span Forward - Word Recall - Verbal fluency, - Clock drawing - Digit span backward 
Singapore category (animals) (Sutherland) - Frontal assessment 
battery 
PITCH Trail Making Test A - FCSRT - Verbal fluency, - Rey Complex - Trail Making Test B 
Digit Span Forward - Rey Complex category Figure Test: Copy - Verbal fluency, letter 
Figure Test: Recall - Token Test - Praxis score - Card Sorting Test 
- Digit Span backward 
- Stroop Test 
PROSPER - Letter Digit Substi- - Picture Learning - Stroop Test 
tution Test test: immediate and 
delayed memory 
- Doors and People 
test 
STRIDE* NA NA NA NA NA 
( Continued) 
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Table 2 
Cognitive measures used by the STROKOG member studies to diagnose dementia (Continued) 
Cognitive domain 
Study 
Attention/processing 
speed Memory Language 
Construction 
(visuospatial) 
Executive function/ 
abstract reasoning 
STROKDEM 
sss 
- Trail Making Test A 
- Zazzo Test 
- Digit Symbol Coding 
- Bell's Test 
- Trail Making Test A 
- Digit Span Forward 
- Mental Control 
- Symbol Digit Mo-
dalities Test 
- Choice Reaction 
Time 
- FCSRT 
- Logical Memory 
I & II 
- Verbal memory 
recall 
- Visual Reproduction 
I & II 
- Visual memory 
recall 
- Verbal fluency, 
category 
- Token Test 
- Boston Naming Test 
- Sentence repetition 
- Verbal fluency, 
category (animals) 
- Token Test 
- VOSP 
- Rey Complex 
Figure Test: Copy 
- Praxis score 
- Block design 
- Simple copying 
- Picture completion 
- Trail Making Test B 
- Verbal fluency, letter 
- Stroop Test 
- Trail Making Test B 
- Digit Span backward 
- Similarities 
- Identities and 
oddities 
- COWAT 
Abbreviations: BADS, behavioral assessment of the dysexecutive syndrome; BDAE, Boston Diagnostic Aphasia Examination; CAMCOG, Cambridge 
Cognitive Examination; CERAD, Consortium to Establish a Registry for Alzheimer's Disease; COWAT, Controlled Oral Word Association Test; CSID, Com-
munity Screening Interview for Dementia; FCSRT, Free and Cued Selective Reminding Test; GIT, Groninger Intelligence Test; HCFD, higher cortical function 
deficits; KSNAP, Kaufman short neuropsychological assessment procedure; RAVLT, Rey Auditory Verbal Learning Test; VOSP, visual object and space percep-
tion battery. 
NOTE. The assignment of a neuropsychological test to a particular cognitive domain is based on convention and previous work such as for COSMIC [ 17] and 
may not be how a study has assigned the test. 
* ASPIRE-S, MSS-II, Giiteborg Neuro70+ and STRIDE did not conduct detailed neuropsychological test batteries, instead, the following tests were used to 
diagnose dementia in each study: ASPIRE-S: MoCA (The Montreal Cognitive Assessment); Giiteborg Neuro70+: Cognitive symptom ratings and items from 
ADAS-Cog (The Alzheimer's Disease Assessment Scale-Cognition); MSS-II: NART (National Adult Reading Test performance in established dementia) was 
conducted for pre-morbid cognitive ability; specific additional tests for current cognition were not performed outside of ACER (Addenbrooke's Cognitive Ex-
amination) and MOCA (equivalent); STRIDE: The Mini-Mental Status Examination (MMSE) and MoCA. 
1Cracow study conducted neuropsychological tests under the five domains but these data were lost and not available. 
studies, for example, for the COSMIC consortium [63]. There 
exists much heterogeneity in measurement instruments used 
by different studies. Even when studies have used similar tests, 
different versions of tests were used, and tests might have been 
administered in nonstandard ways. Owing to differences in cul-
ture and language, questions and responses may have been 
worded differently. There is no consensus on how each neuro-
psychological test should be allocated to a specific cognitive 
domain as such tests are generally multifactorial. Table 2 shows 
the list of tests used in the studies under five cognitive domains; 
each test was assigned to a cognitive domain based on 
convention and previous work such as for COSMIC [63]. 
Demographic effects such as age, gender, and education need 
to be accounted for. Furthermore, adequate normative data 
may or may not be available in all regions or for all ethnocul-
tural groups; not all studies included nondemented stroke-free 
controls whose test scores may be used to derive adjusted scores 
and to define cognitive impairment. 
3.2. Advantages 
The benefits of being able to reuse, combine, and compare 
data from multiple cohorts are obvious, and this approach has 
been recommended by the Lancet REW ARD Campaign [64]. 
Cohort studies focused on stroke and cognition are expen-
sive, labor-intensive, and very demanding of researchers' 
and participants' time. Multiple factors may limit the study 
sample size and duration. There already exists a wealth of 
data from previous or current studies that are underutilized 
and can be put to further use. Standard meta-analysis is one 
way of analyzing the combined cohorts of existing studies, 
but it is limited to published results and specific research 
questions. STROKOG's approach in harmonizing individual 
participant data from various studies is an economical use of 
previously collected data to explore both existing and novel 
research questions. According to the Cochrane Methods 
group, IPD meta-analyses are considered the "gold standard" 
of systematic review [65]. In IPD meta-analyses, individual 
participant data from all studies can be modeled simulta-
neously while accounting for the clustering of participants 
within studies [17]. It allows detailed participant-level explo-
ration of cognitive disorders in relation to the individuals' 
characteristics. Additionally, statistical analysis can be stan-
dardized across studies where more appropriate or advanced 
methods can be used; baseline and potential confounding fac-
tors can be adjusted for consistency across studies; results for 
missing or poorly acquired outcomes can be reported, 
thereby reducing bias within study reporting; results for spe-
cific subgroups of participants can be obtained across studies; 
unpublished data can be included, thereby addressing publi-
cation bias [17]. Having access to a rich collection of individ-
ual participant-level data from international studies, 
STROKOG is in a unique position to apply IPD meta-
analyses techniques and fully explore and examine patient 
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level characteristics and outcomes, which in tum could lead 
to facilitating a better understanding of various aspects of 
post-stroke cognitive impairment. 
A consortium such as STROKOG has the added benefit of 
informing new researchers of the need to standardize their mea-
sures and methods so that they are in step with other researchers 
in the same field. This is particularly important for stroke and 
dementia, as many researchers from low and middle income 
countries have recently become interested in this topic and 
are mounting studies that would benefit from comparability 
with existing studies. New studies therefore would have the 
benefit of validated measures and better comparability. 
There is also the potential for the STROKOG database to 
be made available to nonconsortium researchers following 
consortium-based publications and with the approval of 
the RSC and the ethics review board. The scientific benefits 
of making large databases available to researchers world-
wide have been demonstrated by the more than 250 publica-
tions that have resulted from the sharing of ADNI 
(Alzheimer's Disease Neuroimaging Initiative) data [66]. 
The research community that STROKOG proposes to 
create is likely to pay other dividends. It is expected that the 
productivity of the group will increase over time in quality 
and quantity; junior researchers will be supported, new ideas 
and lines of investigation will be generated and scientific inter-
change and collaboration will be facilitated. The benefits will 
therefore extend beyond the harmonizing and pooling of data. 
3.3. Specific projects 
The first project aims to describe the prevalence and profile 
of poststroke cognitive impairment, measured between 1 and 
6 months after a stroke or TIA, in diverse geographical and eth-
nocultural settings as represented by the STROKOG member 
cohorts. The project is currently underway and is being coordi-
nated by the Sydney team. A project proposal was approved by 
the RSC, and the following data are currently being requested: 
1. Demographics. 
2. Stroke-related variables. 
3. Medical history/risk factors. 
4. Functional assessments and screening tests. 
5. Neuropsychological test data. 
6. Neurological assessments and psychiatric examina-
tions. 
7. Cognitive disorder diagnosis. 
A number of projects utilizing STROKOG data have been 
proposed for the future, and they aim to examine across 
STROKOG cohorts 
l. Rates of cognitive decline in post-stroke patients. 
2. Determinants of cognitive impairment. 
3. Determinants of cognitive decline. 
4. Effect of methodologic differences in the collection 
and interpretation of cognitive data on the estimation 
of prevalence of cognitive deficit. 
5. Specific risk factors such as atrial fibrillation, conges-
tive heart failure, diabetes, and homocysteine. 
6. Depression and apathy in relation to cerebrovascular 
disease. 
7. Relative contributions of Alzheimer's and vascular pa-
thologies to dementia. 
8. Precise and reliable quantitation and localization of 
white-matter hyperintensities, microbleeds, lacunes 
and micro-infarcts and examination of their relation-
ship to cognition. 
While many of the existing member studies have relevant 
data to contribute to the more general topics (such as 1 to 4 
noted above), the more specific topics (5 to 8) will be best 
addressed by growing the STROKOG membership base. 
Therefore, we encourage any investigators with a study 
meeting the eligibility criteria to contact STROKOG and 
become a member of the consortium. 
4. Conclusion 
STROKOG is a truly international consortium of studies 
with a focus on cognitive disorders associated with cerebro-
vascular disease. It has the potential to transform our under-
standing of the epidemiology and natural course of VCD and 
have a worldwide impact on promoting better cognitive out-
comes in the setting of cerebrovascular disease. 
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RESEARCH IN CONTEXT 
1. Systematic review: The authors performed a review 
of published studies of poststroke cognitive impair-
ment and dementia using PubMed and invited all 
eligible studies to participate. Unpublished studies 
were identified through correspondence with mem-
bers of the Society for Vascular Cognitive and 
Behavioral Disorders (VASCOG). 
2. Interpretation: The STROKOG consortium brings 
together international longitudinal cohort studies of 
cognitive decline and dementia following stroke or 
TIA. By harmonizing data and conducting individual 
participant meta-analyses, STROKOG aims to better 
understand the determinants and manifestations of 
vascular contributions to cognitive disorders and 
help improve the diagnosis and treatment of vascular 
cognitive disorders. 
3. Future directions: STROKOG will conduct individ-
ual projects investigating research topics such as 
the prevalence of VCD, rates of cognitive decline, 
determinants of cognitive impairment and the fre-
quency of depression in relation to cerebrovascular 
disease. STROKOG invites other longitudinal 
studies on stroke/TIA patients and cognitive impair-
ment to join, contribute to the database and partici-
pate in collaborative research. 
References 
[l] Roman GC. Managing Vascular Dementia. London: Science Press; 
2003. 
[2] Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, 
Breteler MM, et al. Prevalence of dementia and major subtypes in Eu-
rope: A collaborative study of population-based cohorts. Neurologic 
Diseases in the Elderly Research Group. Neurology 2000;54:S4-9. 
[3] Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, 
McDowell I. Prevalence and outcomes of vascular cognitive impair-
ment. Neurology 2000;54:447-51 . 
[4] Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, 
Kaste M. Clinical determinants of poststroke dementia. Stroke 1998; 
29:75- 81. 
[5] Sachdev PS, Brodaty H, Valenzuela MJ, Lorentz L, Looi JCL, 
Berman K, et al. Clinical determinants of dementia and mild cognitive 
impairment following ischaernic stroke: the Sydney Stroke Study. De-
ment Geriatr Cogn Disord 2006;21:275-83. 
[6] Makin S, Turpin S, Dennis M, Wardlaw J. Cognitive impairment after 
lacunar stroke: systematic review and meta-analysis of incidence, 
prevalence and comparison with other stroke sub-types. J Neural Neu-
rosurg Psychiatry 2013;84:893-900. 
[7] Desmond DW, Moroney IT, Paik MC, Sano M, Mohr JP, Aboumatar S, 
et al. Frequency and clinical determinants of dementia after ischernic 
stroke. Neurology 2000;54:1124-31. 
22 P.S. Sachdev et al. I Alzheimer:S & Dementia: Diagnosis, Assessment & Disease Monitoring 7 (2017) 11-23 
[8] Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors asso-
ciated with pre-stroke and post-stroke dementia: a systematic review 
and meta-analysis. Lancet Neurol 2009;8:1006-18. 
[9] Savva GM, Stephan BC, the Alzheimer's Society Vascular Dementia 
Systematic Review Group. Epidemiological studies of the effect of 
stroke on incident dementia: A systematic review. Stroke 2010; 
41:e41-6. 
[10] Sposato LA, Kapral MK, Fang J, Gill SS, Hackam DG, Cipriano LE, 
et al. Declining incidence of stroke and dementia: coincidence or pre-
vention opportunity? JAMA Neurol 2015;72:1529-31. 
[11] Pendlebury ST. Stroke-related dementia: rates, risk factors and impli-
cations for future research. Maturitas 2009;64:165-71. 
[12] Allan L, Rowan EN, Firbank MJ, Thomas AJ, Parry SW, 
Polvikoski TM, et al. Long term incidence of dementia, predictors 
of mortality and pathological diagnosis in older stroke survivors. Brain 
2011;134:3713-24. 
[13] Ivan CS, Seshadri S, Beiser A, Au R, Kase CS, Kelly-Hayes M, et al. 
Dementia after stroke: the Framingham Study. Stroke 2004;35: 1264--8. 
[14] Gottesman RF, Hills AE. Predictors and assessment of cognitive 
dysfunction resulting from ischaemic stroke. Lancet Neurol 2010; 
9:895-905. 
[15] Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, 
Iadecola C, et al. Vascular contributions to cognitive impairment and de-
mentia: a statement for healthcare professionals from the american heart 
association/american stroke association. Stroke 2011;42:2672-713. 
[16] METACOHORTS Consortium. METACOHORTS for the study of 
vascular disease and its contribution to cognitive decline and neurode-
generation: An initiative of the Joint Progranune for Neurodegenera-
tive Disease Research. Alzheimers Dement 2016; http://dx.doi.org/ 
10.1016/j.jalz.2016.06.004 [Epub ahead of print]. 
[17] Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual 
participant data: rationale, conduct, and reporting. BMJ 2010; 
340:521- 5. 
[18] Lyman GH, Kuderer NM. The strengths and limitations of meta-
analyses based on aggregate data. BMC Med Res Methodol 2005 ;5: 14. 
[19] Mellon L, Brewer L, Hall P, Horgan F, Williams D, Hickey A, et al. 
Cognitive impairment six months after ischaemic stroke: a profile 
from the ASPIRE-S study. BMC Neurol 2015;15. 
[20] Lim JS, Kim N, Jang MU, Han MK, Kim S, Baek MJ, et al. Cortical 
hubs and subcortical cholinergic pathways as neural substrates of post-
stroke dementia. Stroke 2014;45:1069- 76. 
[21] Ducroquet A, Leys D, Saabi AA, Richard F, Cordonnier C, Girot M, et al. 
Influence of chronic ethanol consumption on the neurological severity 
in patients with acute cerebral ischemia. Stroke 2013;44:2324--6. 
[22] Douven E, Schievink SH, Verhey FR, van Oostenbrugge JR, Aalten P, 
Staats J, et al. The Cognition and Affect after Stroke - a Prospective 
Evaluation of Risks (CASPER) study: rationale and design. BMC 
Neurol 2016;16:65. 
[23] Brodtmann A, Werden E, Pardoe H, Li Q, Jackson G, Cowie T, et al. 
Charting cognitive and volumetric trajectories after stroke: protocol 
for the Cognition And Neocortical Volume After Stroke (CANVAS) 
study. Int J Stroke 2014;9:824--8. 
[24] Akinyemi RO, Allan L, Owolabi MO, Akinyemi JO, Ogbole G, 
Ajani A, et al. Profile and determinants of vascular cognitive impair-
ment in African stroke survivors: The CogFAST - Nigeria Study. J 
Neurol Sci 2014;346:241-9. 
[25] Dong Y, Venketasubrarnanian N, Poon-Lap Chan BP, Sharma VK, 
Slavin MJ, Collinson SL, et al. Brief screening tests during acute 
admission in patients with mild stroke are predictive of vascular cogni-
tive impairment 3-6 months after stroke. J Neurol Neurosurg Psychia-
try 2012;83:580-5. 
[26] Klimkowicz A, Dziedzic T, Polczyk R, Pera J, Slowik A, Szczudlik A. 
Factors associated with pre-stroke dementia: the cracow stroke data-
base. J Neurol 2004;251:599- 603. 
[27] Klirnkowicz-Mrowiec A, Dziedzic T, Slowik A, Szczudlik A. Predic-
tors of poststroke dementia: results of a hospital-based study in Poland. 
Dement Geriatr Cogn Disord 2006;21 :328- 34. 
[28] Wollenweber FA, Zietemann V, Rominger A, Opherk C, Bayer-
Karpinska A, Gschwendtner A. The Determinants of Dementia After 
Stroke (OEDEMAS) Study: protocol and pilot data. Int J Stroke 
2014;9:387-92. 
[29] Hoffmann M. Stroke in the young: The multiethnic prospective durban 
stroke data bank results. J Stroke Cerebrovasc Dis 1998;7:404-13. 
[30] Hoffmann M. Higher cortical function deficits after stroke: an analysis 
of 1,000 patients from a dedicated cognitive stroke registry. Neurore-
habil Neural Repair 2001;15:113-27. 
[31] Desmond DW, Moroney IT, Sano M, Stem Y. Incidence of dementia after 
ischemic stroke: results of a longitudinal study. Stroke 2002;33 :2254--60. 
[32] Linden T, Skoog I, Fagerberg B, Steen B, Blomstrand C. Cognitive 
impairment and dementia 20 months after stroke. Neuroepidemiology 
2004;23:45-52. 
[33] Linden T, Blomstrand C, Skoog I. Depressive disorders after 20 months 
in elderly stroke patients: a case-control study. Stroke 2007;38:1860-3. 
[34] Godefroy 0, Leclercq C, Roussel M, Moroni C, Quaglino V, 
Beaunieux H. French adaptation of the vascular cognitive impairment 
harmonization standards: the GRECOG-VASC study. Int J Stroke 
2012;7:362-3. 
[35] Jokinen H, Melkas S, Ylikoski R, Pohjasvaara T, Kaste M, 
Erkinjuntti T, et al. Post-stroke cognitive impairment is common 
even after successful clinical recovery. Eur J Neurol 2015; 
22: 1288-94. 
[36] Oksala N, Jokinen H, Melkas S, Oksala A, Pohjasvaara T, Hietanen M, 
et al. Cognitive impairment predicts poststroke death in long-term 
follow up. J Neurol Neurosurg Psychiatry 2009;80:1230-5. 
[37] Rasquin SM, Lodder J, Verhey FR. The effect of different diagnostic 
criteria on the prevalence and incidence of post-stroke dementia. Neu-
roepidemiology 2005;24:189-95. 
[38] Heye AK, Thrippleton MJ, Armitage PA, Valdes Hernandez Mdel C, 
Makin SD, Glatz A, et al. Tracer kinetic modelling for DCE-MRI 
quantification of subtle blood-brain barrier permeability. Neuroimage 
2016;125:446-55. 
[39] Heye AK, Thrippleton MJ, Chappell FM, Valdes Hernandez MD, 
Armitage PA, Makin SD, et al. Blood pressure and sodium: association 
with MRI markers in cerebral small vessel disease. J Cereb Blood 
Flow Metab 2016;36:264--74. 
[40] Valdes Hernandez Mdel C, Armitage PA, Thrippleton MJ, 
Chappell F, Sandeman E, Munoz Maniega S, et al. Rationale, design 
and methodology of the image analysis protocol for studies of 
patients with cerebral small vessel disease and mild stroke. Brain Be-
hav 2015;5:e00415. 
[41] Yu KH, Cho SJ, Oh MS, Jung S, Lee JH, Shin JH, et al. Cognitive 
impairment evaluated with Vascular Cognitive Impairment Harmoni-
zation Standards in a multicenter prospective stroke cohort in Korea. 
Stroke 2013;44:786-8. 
[42] Srikanth VK, Quinn SJ, Donnan GA, Saling MM, Thrift AG. Long-
term cognitive transitions, rates of cognitive change, and predictors 
of incident dementia in a population-based first-ever stroke cohort. 
Stroke 2006;37:2479- 83. 
[43] Srikanth V, Anderson JF, Donnan GA, Saling MM, Didus E, 
Alpitsis R, et al. Progressive dementia after first-ever stroke: a 
community-based follow-up study. Neurology 2004;63:785-92. 
[44] Srikanth VK, Thrift AG, Saling MM, Anderson JF, Dewey HM, 
Macdonell RA. Increased risk of cognitive impairment 3 months after 
mild to moderate first-ever stroke: a Community-Based Prospective Study 
of Nonaphasic English-Speaking Survivors. Stroke 2003;34:1136-43. 
[45] Kandiah N, Wiryasaputra L, Narasirnhalu K, Karandikar A, 
Marmin M, Chua EV, et al. Frontal subcortical ischemia is crucial 
for post stroke cognitive impairment. J Neurol Sci 2011 ;309:92-5. 
[ 46] Kandiah N, Goh 0, Mak E, Marmin M, Ng A. Carotid stenosis: A risk 
factor for white-matter disease. J Stroke Cerebrovasc Dis 2014; 
23:136-9. 
[47] Kandiah N, Chander RJ, Lin XL, Ng A, Poh YY, Cheong CY, et al. 
Cognitive impairment after mild stroke: Development and validation 
of the SIGNAL2 Risk Score. J Alzheirners Dis 2016;49:1169- 77. 
P.S. Sachdev et al. I Alzheimer:S & Dementia: Diagnosis, Assessment & Disease Monitoring 7 (2017) 11-23 23 
[48] Cordonnier C, Leys D, Dumont F, Deramecourt V, Bordet R, 
Pasquier F, et al. What are the causes of pre-existing dementia 
in patients with intracerebral haemorrhages? Brain 2010; 
133:3281-9. 
[49] Moulin S, Labreuche J, Bombois S, Rossi C, Boulouis G, Henon H, 
et al. Dementia risk after spontaneous intracerebral haemorrhage: a 
prospective cohort study. Lancet Neurol 2016;15:820-9. 
[50] Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, 
Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular 
disease (PROSPER): a randomised controlled trial. Lancet 2002; 
360: 1623-30. 
[51] YangJ, Wong A, WangZ,Liu W,AuL, XiongY, etal. Risk factors for 
incident dementia after stroke and transient ischemic attack. Alz-
heimers Dement 2015;11:16-23. 
[52] Liu W, Wong A, Au L, Yang J, Wang Z, Leung EY, et al. Influence of 
amyloid-13 on cognitive decline after stroke/transient ischemic attack: 
three-year longitudinal study. Stroke 2015;46:3074-80. 
[53] Wang Z, Wong A, Liu W, Yang J, Chu WC, Au L, et al. Cerebral micro-
bleeds and cognitive function in ischemic stroke or transient ischemic 
attack patients. Dement Geriatr Cogn Disord 2015;40:130-6. 
[54] Wang Z, Wong A, Liu W, Yang J, Chu WC, Au L, et al. Pulse pressure 
and cognitive decline in stroke patients with white matter changes. J 
Clin Hypertens (Greenwich) 2015;17:694-8. 
[55] Mok VC, Lam BY, Wang Z, Liu W, Au L, Leung EY, et al. Delayed-
onset dementia after stroke or transient ischemic attack. Alzheimers 
Dement 2016;12:1167- 76. 
[56] Sachdev PS, Brodaty H, Valenzuela MJ, Lorentz L, Looi JC, Wen W, 
et al. The neuropsychological profile of vascular cognitive impairment 
in stroke and TIA patients. Neurology 2004;62:912-9. 
[57] Sachdev PS, Lipnicki DM, Crawford JD, Wen W, Brodaty H. Progres-
sion of cognitive impairment in stroke/TIA patients over 3 years. J 
Neurol Neurosurg Psychiatry 2014;85:1324-30. 
[58] Fortier I, Raina P, Van den Heuvel ER, Griffith LE, Craig C, Saliba M, 
et al. Maelstrom Research guidelines for rigorous retrospective data 
harmonization. IntJEpidemiol 2016. pii: dyw075. [Epub ahead of print]. 
[59] Stewart GB, Altman DG, Askie LM, Duley L, Simmonds MC, 
Stewart LA. Statistical analysis of individual participant data meta-
analyses: a comparison of methods and recommendations for practice. 
PLoS One 2012;7:e46042. 
[60] Psaty BM, O'Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, 
Rotter JI, et al. Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) Consortium: Design of prospective meta-
analyses of genome-wide association studies from five cohorts. Circ 
Cardiovasc Genet 2009;2:73-80. 
[61] Schaap LA, Peeters GM, Dennison EM, Zambon S, Nikolaus T, San-
chez-Martinez M, et al. European Project on OSteoArthritis (EPOSA): 
methodological challenges in harmonization of existing data from five 
European population-based cohorts on aging. BMC Musculoskelet 
Disord 2011;12:272. 
[62] Pluijm SM, Hardage C, Nikula S, Blumstein T, Jylha M, Minicuci N, 
et al. A harmonized measure of activities of daily living was a reliable 
and valid instrument for comparing disability in older people across 
countries. J Clin Epidemiol 2005;58:1015-23. 
[63] Sachdev PS, Lipnicki DM, Kochan NA, Crawford JD, Thalamuthu A, 
Andrews G, et al. The prevalence of mild cognitive impairment in 
diverse geographical and ethnocultural regions: The COSMIC Collab-
oration. PLoS One 2015;10:e0142388. 
[64] REWARD. The Lancet. Available at: http://www.thelancet.com/ 
campaigns/efficiency/statement. Accessed June 01 , 2016. 
[65] Cochrane Methods: IPD Meta-analysis. The Cochrane collaboration. Avail-
able at http://methods.cochrane.org/ipdrna/. Accessed August 22, 2016. 
[66] Carrillo MC, Bain LJ, Frisoni GB, Weiner MW. Worldwide Alz-
heimer's disease neuroimaging initiative. Alzheimers Dement 2012; 
8:337-42. 
